X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (71) 71
index medicus (55) 55
gastroenterology & hepatology (48) 48
male (48) 48
female (46) 46
middle aged (46) 46
adult (40) 40
aged (30) 30
hepatitis (30) 30
life sciences (24) 24
hepatitis c, chronic - drug therapy (22) 22
hepatitis c virus (21) 21
hepatitis c (20) 20
interferon (20) 20
liver (20) 20
antiviral agents - therapeutic use (18) 18
hepacivirus - genetics (18) 18
infection (18) 18
treatment outcome (18) 18
cirrhosis (17) 17
infections (17) 17
hepatitis c, chronic - complications (16) 16
ribavirin (16) 16
hepatitis c, chronic - virology (15) 15
patients (15) 15
drug therapy, combination (14) 14
genotype (14) 14
health aspects (13) 13
abridged index medicus (12) 12
therapy (12) 12
young adult (12) 12
drug therapy (11) 11
hepatocellular-carcinoma (11) 11
infectious diseases (11) 11
liver cancer (11) 11
liver cirrhosis (11) 11
liver cirrhosis - virology (11) 11
viral load (11) 11
genotype & phenotype (10) 10
liver diseases (10) 10
clinical trials (9) 9
fibrosis (9) 9
france (9) 9
hepatitis b (9) 9
mortality (9) 9
analysis (8) 8
care and treatment (8) 8
hiv (8) 8
hiv infections - complications (8) 8
human health and pathology (8) 8
interferon-alpha - therapeutic use (8) 8
medicine (8) 8
prospective studies (8) 8
retrospective studies (8) 8
ribavirin - therapeutic use (8) 8
rna, viral - blood (8) 8
science (8) 8
virus-infection (8) 8
[sdv]life sciences [q-bio] (7) 7
chronic infection (7) 7
digestive system diseases (7) 7
hcv (7) 7
hepatitis c - complications (7) 7
human immunodeficiency virus--hiv (7) 7
internal medicine (7) 7
liver cirrhosis - complications (7) 7
ribavirin - administration & dosage (7) 7
sofosbuvir (7) 7
sustained virological response (7) 7
virus diseases (7) 7
viruses (7) 7
aged, 80 and over (6) 6
antiviral agents - administration & dosage (6) 6
antiviral agents - adverse effects (6) 6
chronic hepatitis-c (6) 6
disease progression (6) 6
follow-up studies (6) 6
gastroenterology and hepatology (6) 6
genetic aspects (6) 6
genotypes (6) 6
hepatology (6) 6
immunology (6) 6
medicine, general & internal (6) 6
multivariate analysis (6) 6
prognosis (6) 6
research (6) 6
research article (6) 6
ribavirin - adverse effects (6) 6
adolescent (5) 5
alanine transaminase - blood (5) 5
aspartate aminotransferases - blood (5) 5
biological response modifiers (5) 5
biopsy (5) 5
boceprevir (5) 5
cancer (5) 5
double-blind method (5) 5
hepacivirus - classification (5) 5
hepatitis b virus (5) 5
hepatitis c - drug therapy (5) 5
hepatitis c, chronic - blood (5) 5
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2015, Volume 386, Issue 10003, pp. 1537 - 1545
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2015, Volume 15, Issue 4, pp. 397 - 404
Journal Article
The Lancet, ISSN 0140-6736, 04/2019, Volume 393, Issue 10179, pp. 1453 - 1464
Journal Article
American Heart Journal, ISSN 0002-8703, 04/2018, Volume 198, pp. 4 - 17
The objective was to examine the role of a sustained virological response (SVR) on major adverse cardiovascular events (MACEs) in patients with compensated... 
ETHNIC-DIFFERENCES | HEART-DISEASE | CARDIAC & CARDIOVASCULAR SYSTEMS | VIRUS-INFECTION | RISK-FACTORS | MYOCARDIAL-INFARCTION | ANTIVIRAL TREATMENT | ANRS CO12 CIRVIR | EXTRAHEPATIC MANIFESTATIONS | PERIPHERAL ARTERIAL-DISEASE | MIXED CRYOGLOBULINEMIA | Immunohistochemistry | Predictive Value of Tests | Age Distribution | Prevalence | Prognosis | Humans | Middle Aged | Cardiovascular Diseases - therapy | Hepatitis C, Chronic - physiopathology | Male | Hepatitis C, Chronic - complications | Cardiovascular Diseases - epidemiology | Female | Retrospective Studies | France | Liver Function Tests | Severity of Illness Index | Cardiovascular Diseases - etiology | Risk Assessment | Antiviral Agents - therapeutic use | Liver Cirrhosis - complications | Kaplan-Meier Estimate | Proportional Hazards Models | Survival Rate | Hepatitis C, Chronic - drug therapy | Liver Cirrhosis - virology | Liver Cirrhosis - pathology | Sex Distribution | Aged | Biopsy, Needle | Cohort Studies | Control | Hepatitis C | Analysis | Myocardial infarction | Heart | Heart attacks | Viremia | Liver | Viruses | Cardiovascular disease | Infections | Bilirubin | Family medical history | Multivariate analysis | Hepatitis | Body mass index | Liver cancer | Ischemia | Blood platelets | Atherosclerosis | Heart diseases | Hypertension | Cerebral infarction | Stroke | Level (quantity) | Mortality | Diabetes mellitus | Albumin | Principal components analysis | Serum albumin | Angina pectoris | Patients | Coronary artery disease | Ethnic factors | Cirrhosis | Biopsy | Coronary vessels | Infarction | Diabetes | Hepatitis C virus | Smoking
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9973, pp. 1087 - 1097
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9986, pp. 2502 - 2509
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9954, pp. 1597 - 1605
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2013, Volume 13, Issue 7, pp. 597 - 605
Summary Background Rates of sustained virological response (SVR) to peginterferon–ribavirin are low in patients with hepatitis C virus (HCV) genotype 1 and... 
Infectious Disease | Humans | Middle Aged | Hepacivirus - genetics | Polyethylene Glycols - adverse effects | Male | RNA, Viral - blood | Hepatitis C, Chronic - complications | Recombinant Proteins - adverse effects | Viral Load | Drug-Related Side Effects and Adverse Reactions - pathology | Young Adult | Drug Therapy, Combination - adverse effects | HIV-1 - isolation & purification | Placebos - adverse effects | Ribavirin - administration & dosage | Adult | Female | Placebos - administration & dosage | Proline - administration & dosage | Hepacivirus - isolation & purification | Double-Blind Method | Proline - analogs & derivatives | HIV Infections - virology | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Drug-Related Side Effects and Adverse Reactions - epidemiology | Interferon-alpha - administration & dosage | Drug Therapy, Combination - methods | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Adolescent | HIV Infections - complications | Aged | Hepacivirus - classification | Interferon-alpha - adverse effects | Medical colleges | Interferon alpha | Clinical trials | HIV (Viruses) | Biological response modifiers | Ribavirin | Viral antigens | Virus diseases | Genetic aspects | Product development | Drug therapy | Hepatitis C virus | HIV infection
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2012, Volume 12, Issue 9, pp. 671 - 677
Journal Article